$CANF Signs $42.7 Million Out-Licensing Deal with Ewopharma

Can-Fite Signs $42.7 Million Out-Licensing Deal with Ewopharma

Swiss Ewopharma to market Piclidenoson and Namodenoson in Central Eastern Europe (CEE)

$2.25 million upfront payment with an additional $40.45 million for regulatory & sales milestones and 17.5% royalties are included

finance.yahoo.com/news/fite-signs-42-7-million-110000152.html